BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

985 related articles for article (PubMed ID: 29390197)

  • 21. [Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis].
    Chen JW; Pang PF; Meng XC; Zhou B; Huang WS; Guo YJ; Zhu KS; Shan H
    Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(9):663-7. PubMed ID: 23751743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.
    Peng Z; Wei M; Chen S; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Kuang M
    Eur Radiol; 2018 Aug; 28(8):3522-3531. PubMed ID: 29536241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
    Feng X; Xu R; Du X; Dou K; Qin X; Xu J; Jia W; Wang Z; Zhao H; Yang S; Guo C; Liu T; Ma K
    Am J Gastroenterol; 2014 Dec; 109(12):1891-9. PubMed ID: 25403366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis.
    Koh PS; Chan AC; Cheung TT; Chok KS; Dai WC; Poon RT; Lo CM
    HPB (Oxford); 2016 Jan; 18(1):72-8. PubMed ID: 26776854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Yang M; Yuan JQ; Bai M; Han GH
    Mol Biol Rep; 2014 Oct; 41(10):6575-82. PubMed ID: 25091939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
    Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
    BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early Stage Hepatocellular Carcinomas Not Feasible for Ultrasound-Guided Radiofrequency Ablation: Comparison of Transarterial Chemoembolization Alone and Combined Therapy with Transarterial Chemoembolization and Radiofrequency Ablation.
    Hyun D; Cho SK; Shin SW; Park KB; Park HS; Choo SW; Do YS; Choo IW; Lee MW; Rhim H; Lim HK
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):417-25. PubMed ID: 26246215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.
    Fu S; Chen S; Liang C; Liu Z; Zhu Y; Li Y; Lu L
    Oncotarget; 2017 Jun; 8(23):37855-37865. PubMed ID: 27911268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
    Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
    Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
    Liu F; Meng Z; Shao G; Wang J; Wang Z; Yang J; Yip CS; He D
    Mol Biol Rep; 2017 Feb; 44(1):149-158. PubMed ID: 27981445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Park HC; Yu JI; Sohn W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2014 May; 34(5):795-801. PubMed ID: 24350564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement.
    Zhao M; Wang JP; Pan CC; Li W; Huang ZL; Zhang L; Fang WJ; Jiang Y; Li XS; Wu PH
    Eur J Radiol; 2012 Oct; 81(10):2717-25. PubMed ID: 22245655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
    Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
    J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].
    Hua XD; He ZY
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):790-2. PubMed ID: 23291076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
    Geschwind JF; Kudo M; Marrero JA; Venook AP; Chen XP; Bronowicki JP; Dagher L; Furuse J; LadrĂ³n de Guevara L; Papandreou C; Sanyal AJ; Takayama T; Ye SL; Yoon SK; Nakajima K; Lehr R; Heldner S; Lencioni R
    Radiology; 2016 May; 279(2):630-40. PubMed ID: 26744927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.